AstraZeneca-The MAVRiC Study - Clinical Trial
Email to Participate
marco.reyes-martinez@duke.edu
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
AstraZeneca AB: The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab
Principal Investigator
Danielle M. Brander, MD
Hematologic Oncologist
Protocol Number
IRB:
PRO00118960
NCT:
NCT07024706
Phase
Phase
II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate